We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
QuantuMDx and SCIENION Partner to Commercialize Novel Nanowire Biosensor
News

QuantuMDx and SCIENION Partner to Commercialize Novel Nanowire Biosensor

QuantuMDx and SCIENION Partner to Commercialize Novel Nanowire Biosensor
News

QuantuMDx and SCIENION Partner to Commercialize Novel Nanowire Biosensor

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "QuantuMDx and SCIENION Partner to Commercialize Novel Nanowire Biosensor"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

QMDx utilizes SCIENION's proprietary ultra-low volume liquid handling technologies to transfer biological material onto QMDx's novel biosensor. Each nanowire in the array is printed with molecular probes; with hundreds of nanowires in each silicon biosensor chip, the multiplexing potential is massive.

The companies' longstanding relationship was cemented with QMDx's purchase of SCIENION's sciFLEXARRAYER SX, and will continue to grow as the companies embark on a number of development projects to take the biosensor characterization from R&D to mass manufacture.
The instrument is the newest fixture in QMDx's chemistry facility at the University of Newcastle upon Tyne's Chemical Nanoscience Laboratories.

QMDx's Head of Chemistry Dr Joseph Hedley said "The flexibility and ease of use of the sciFLEXARRAYER SX has enabled a rapid ramp up in QMDx's R&D activities, and we look forward to working with them on a number of exciting projects that will help bring this device to market."

"We're thrilled to be working with QuantuMDx" said Holger Eickhoff, CEO of SCIENION. "I look forward to our collaboration and believe that our work together will produce some fantastic developments that help foster some disruptive diagnostic innovations."

Advertisement